

Remarks

The Notice to Comply mailed September 24, 2002, has been received and reviewed. Responsive thereto, enclosed is a copy of the Notice to Comply, along with the following items in connection with the above-referenced application: Statement under 37 C.F.R. §§1.821 through 1.825, paper copies of sequence listing (one underlined, one not), CRF copy of sequence listing. It is respectfully submitted that the specification, as originally filed, supports the SEQUENCE LISTING included herein. It is respectfully submitted that this amendment includes no new matter.

Conclusion

Should the Office determine that additional issues remain, which might be resolved by a telephone conference, it is respectfully invited to contact applicants' undersigned attorney.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: October 24, 2002

Enclosures:

Copy of Notice to Comply
Statement per 37 C.F.R. §§ 1.821 through 1.825
Paper copies of the substitute SEQUENCE LISTING
CRF copy of the substitute SEQUENCE LISTING



VERSION WITH MARKINGS TO SHOW CHANGES MADE

AFTER THE SPECIFICATION AND BEFORE THE CLAIMS:

SEQUENCE LISTING

<110> Meloen, Robert H

Oonk, Hendrica B

<120>

PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICAL
PREPARATION, A METHOD TO IMMUNISE ANIMALS AGAINST THE HORMONE
LHRH, AND ANALOGS OF THE LHRH TANDEM REPEAT PEPTIDE AND THEIR USE
AS VACCINE

<130> 3516.2US

<140> US 09/876,257

<141> 2001-06-06

<160> 6

<170> PatentIn version 3.1

<210> 1

<211> 10

<212> PRT

<213> Unknown

<220>

<223> Luteinising Hormone Releasing Hormone (LHRH) from the hypothalamus of an
undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (10)..(10)

<223> X at position 10 = glycine amide

<400> 1

Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa

1 5 10

<210> 2

<211> 21

<212> PRT

NOT ENTERED

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = preferably pyroglutamic acid, but can also be glutamine having attached thereto a tail comprising one or more additional amino acids

<220>

<221> misc feature

<222> (3)..(3)

<223> X at position 3 = tryptophan or formylated tryptophan

<220>

<221> misc feature

<222> (14)..(14)

<223> X at position 14 = tryptophan or formylated tryptophan

<220>

<221> misc feature

<222> (10)..(20)

<223> The sequence comprising residues 10-20 may be repeated.

<220>

<221> misc feature

<222> (21)..(21)

<223> X at position 21 = either nothing or a tail comprising additional amino acid; preferably Cys, the C terminal cysteine being added in connection with a possible coupling of the peptide to a carrier protein.

<400> 2

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly

1 5 10 15

Leu Arg Pro Gly Xaa

 20

<210> 3

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (3)..(3)

<223> X at position 3 = tryptophan or N-formyl-Trp

<220>

<221> misc feature

<222> (13)..(13)

<223> X at position 13 = tryptophan or N-formyl-Trp

<220>

<221> misc feature

<222> (10)..(19)

<223> The sequence comprising residues 10-19 may be repeated.

<400> 3

Xaa His Xaa Ser Tyr Gly Leu Arg Pro Gly Gln His Xaa Ser Tyr Gly
1 5 10 15

Leu Arg Pro Gly Cys
 20

<210> 4

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (6)..(6)

<223> X at position 6 = a possible replacement of glycine by a dextrorotatory amino acid which in addition contains a side chain by which the LHRH tandem unit can be coupled to a carrier compound.

<220>

<221> misc feature

<222> (16)..(16)

<223> X at position 16 = a possible replacement of glycine by a dextrorotatory amino acid which in addition contains a side chain by which the LHRH tandem unit can be coupled to a carrier compound.

<400> 4

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Gln His Trp Ser Tyr Xaa
1 5 10 15

Leu Arg Pro Gly Cys
20

<210> 5

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (1)..(1)

<223> X at position 1 = pyroglutamic acid

<220>

<221> misc feature

<222> (6)..(6)

<223> X at position 6 = Gly or a dextrorotatory amino acid containing a side chain that allows coupling to a carrier compound.

<400> 5

Xaa His Trp Ser Tyr Xaa Leu Arg Pro Gly Cys
1 5 10

<210> 6

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Vaccine against LHRH from the
hypothalamus of an undisclosed mammal.

<220>

<221> misc feature

<222> (21)..(21)

<223> X at position 21 = Cys

<220>

<221> misc feature

<222> (1)..(21)

<223> The initial cysteine of the peptide comprising
residues 1-21 is joined to the initial cysteine of an identical peptide (residues 2
2-42) to form a dimer.

<400> 6

Cys Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr
1 5 10 15

Gly Leu Arg Pro Gly Xaa
 20